Welcome To Our Website!SALES DEPT:info@puresynmr.com

ProductsHome>Products

SARMS/ENDUROBOL (GW-501516)/CARDARINE/selective androgen receptor modulator

CAS#: 317318-70-0
Product Price: Contact us to get the latest price
Product Specification : 98%
Minmum Order Quantity : >50g
Sample Requirement : Free Sample / Freight Charged / to final agreement
Product No.: PUREUBOL

Product Introduction

What is ENDUROBOL (GW-501516)?

ENDUROBOL (GW501516 or GSK-516) is a PPARδ receptor agonist that was previously investigated for drug use.

ENDUROBOL is a selective agonist with high affinity and it is very potent. Various studies on this PPAR receptor in lab indicates that it regulates the various proteins that the body uses for energy.

ENDUROBOL can help to reduce and even reverse various problems in men who are obese or that have symptoms of pre-diabetes due to problems with their metabolism. The use of GW-501516 is viable treatment for reducing obesity and various conditions that are linked to it.

How it works?

ENDUROBOL is a selective agonist (activator) of the PPARδ receptor. It displays high affinity (Ki = 1 nM) and potency (EC50 = 1 nM) for PPARδ with > 1000 fold selectivity over PPARα and PPARγ.

It activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue, and GW 501516 has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome, most likely by stimulating fatty acid oxidation. It has been proposed as a potential treatment for obesity and related conditions, especially when used in conjunction with a synergistic compound AICAR, as the combination has been shown to significantly increase exercise endurance in human.

Dosages and Suggestion

Recommended maximum dose ENDUROBOL is 10 mg per day but many people use as much as 20 mg per day to burn as much fat as they can in in the 8 week cycle.

SARMS We offer

AICAR

2627-69-2

acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown

MK2866

841205-47-8

medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy.

MK-677

15972-10-0

A growth hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly

LGD-4033

1165910-22-4

pharmacological profile similar to that of enobosarm, Ostarine,MK-2866

GW501516

317318-70-0

For obesity, diabetes, dyslipidemia and cardiovascular disease

Andarine(S4)

401900-40-0

partial agonist, intended mainly for treatment of benign prostatic hypertrophy

SR9009

1379686-30-2

under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice

SR9011

1379686-30-2

For obesity, diabetes, dyslipidemia and cardiovascular disease

RAD140

1182367-47-0

New generation for gaining mass and cutting edges

YK11

366508-78-3

431579-34-9

a SARM and myostatin inhibitor in one

GHRP-2

158861-67-7

Growth Hormone Releasing Peptide-2

GHRP-6

87616-84-0

Growth Hormone Releasing Peptide-6

TB500

107761-42-2

Thymosin beta 4

SM130,686

/

/

Copyright © 2012 SYNMR All Rights Reserved. Design by Baiqi